Merck Gets EU Nod for U.S. Biotech Millipore Buy

German drugmaker Merck secured EU regulatory approval on Wednesday for its takeover of U.S. biotech tool maker Millipore, marking a diversification away from the pharmaceuticals business.

Merck, maker of the multiple sclerosis drug Rebif and owner of the rights to cancer drug Erbitux in Europe, unveiled the $6 billion deal in March. Analysts had said the transaction made sense as Merck's liquid crystals unit, its main cash cow, faces increasing competition from Asian rivals.

"Although the parties are both active in the life science business, they focus on different markets," the European Commission said in a statement.

The two groups' activities overlap modestly in the market for air monitoring systems, but their combined market shares remained relatively low, the Commission said.

Given the presence of strong competitors, the Commission concluded that the transaction did not raise competition concerns. Millipore makes filters and purifiers for laboratory water and other materials used in making biotechnology drugs.

Read CHEManager Europe's interview with Merck Chairman Dr. Karl-Ludwig Kley here.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Free Virtual Event

Sustainability in Bioprocessing
Bioprocess Forum

Sustainability in Bioprocessing

Join us to explore hot topics in sustainable bioprocessing like the industrial potential of enzymatic synthesis, innovative biocatalysis techniques, and the use of digital twins in bioprocessing.